Cardiff Oncology Inc (CRDF) Stock: More Strategic Than Meets the Eye
Craig Hallum has recently initiated Cardiff Oncology Inc (CRDF) stock to Buy rating, as announced on September 6, 2024, according to Finviz. Earlier, on January 5, 2022, William Blair had initiated the stock to Outperform. Robert W. Baird also initiated Outperform rating with a price target of $19. Additionally, Maxim Group resumed Buy rating on […]
What’s Fueling Cardiff Oncology Inc (CRDF) Stock’s 7.23% Gain Above Its 200-Day SMA?
Craig Hallum has recently initiated Cardiff Oncology Inc (CRDF) stock to Buy rating, as announced on September 6, 2024, according to Finviz. Earlier, on January 5, 2022, William Blair had initiated the stock to Outperform. Robert W. Baird also initiated Outperform rating with a price target of $19. Additionally, Maxim Group resumed Buy rating on […]
What’s Driving Cardiff Oncology Inc (CRDF) Stock’s 16.85% Surge Over the Past Month?
Craig Hallum has recently initiated Cardiff Oncology Inc (CRDF) stock to Buy rating, as announced on September 6, 2024, according to Finviz. Earlier, on January 5, 2022, William Blair had initiated the stock to Outperform. Robert W. Baird also initiated Outperform rating with a price target of $19. Additionally, Maxim Group resumed Buy rating on […]
Stock Shock: The Unpredictable Rise and Fall of CRDF—What’s Driving the Drama?
Craig Hallum has recently initiated Cardiff Oncology Inc (CRDF) stock to Buy rating, as announced on September 6, 2024, according to Finviz. Earlier, on January 5, 2022, William Blair had initiated the stock to Outperform. Robert W. Baird also initiated Outperform rating with a price target of $19. Additionally, Maxim Group resumed Buy rating on […]
Cardiff Oncology Inc (CRDF) Stock Surge: The Transparent Factors Exposed
Craig Hallum has recently initiated Cardiff Oncology Inc (CRDF) stock to Buy rating, as announced on September 6, 2024, according to Finviz. Earlier, on January 5, 2022, William Blair had initiated the stock to Outperform. Robert W. Baird also initiated Outperform rating with a price target of $19. Additionally, Maxim Group resumed Buy rating on […]
Why Did Cardiff Oncology Inc (CRDF) Stock See 17.12% Surge in the Last 90 Days?
Craig Hallum has recently initiated Cardiff Oncology Inc (CRDF) stock to Buy rating, as announced on September 6, 2024, according to Finviz. Earlier, on January 5, 2022, William Blair had initiated the stock to Outperform. Robert W. Baird also initiated Outperform rating with a price target of $19. Additionally, Maxim Group resumed Buy rating on […]
CRDF Unveiled: The Shocking Truth Behind Cardiff Oncology Inc’s Latest Stock Movements
Craig Hallum has recently initiated Cardiff Oncology Inc (CRDF) stock to Buy rating, as announced on September 6, 2024, according to Finviz. Earlier, on January 5, 2022, William Blair had initiated the stock to Outperform. Robert W. Baird also initiated Outperform rating with a price target of $19. Additionally, Maxim Group resumed Buy rating on […]
Cardiff Oncology Inc (CRDF) Stock Price Reaches $2.58: What Factors Are Influencing This Level?
Craig Hallum has recently initiated Cardiff Oncology Inc (CRDF) stock to Buy rating, as announced on September 6, 2024, according to Finviz. Earlier, on January 5, 2022, William Blair had initiated the stock to Outperform. Robert W. Baird also initiated Outperform rating with a price target of $19. Additionally, Maxim Group resumed Buy rating on […]
Why Did Cardiff Oncology Inc (CRDF) Stock Plunge -1.17% Last Week?
Craig Hallum has recently initiated Cardiff Oncology Inc (CRDF) stock to Buy rating, as announced on September 6, 2024, according to Finviz. Earlier, on January 5, 2022, William Blair had initiated the stock to Outperform. Robert W. Baird also initiated Outperform rating with a price target of $19. Additionally, Maxim Group resumed Buy rating on […]
Cardiff Oncology Inc (CRDF) Stock Posted a Gross Margin of 37.29% Over the Past Year: Is This Justifiable?
Craig Hallum has recently initiated Cardiff Oncology Inc (CRDF) stock to Buy rating, as announced on September 6, 2024, according to Finviz. Earlier, on January 5, 2022, William Blair had initiated the stock to Outperform. Robert W. Baird also initiated Outperform rating with a price target of $19. Additionally, Maxim Group resumed Buy rating on […]